What is Fisetin?
Fisetin is the senolytic you can buy at any supplement store. It's a flavonoid found naturally in strawberries and other fruits, available as an inexpensive capsule without a prescription, and identified by the Kirkland lab at Mayo Clinic as the most potent senolytic activity among 10 flavonoids screened. For the longevity community that finds dasatinib (a prescription cancer drug) too inaccessible and FOXO4-DRI (an injectable research peptide) too novel, fisetin is the natural starting point for senolytic protocols.
The Kirkland lab's 2018 EBioMedicine screening paper compared 10 flavonoids for senolytic activity. Fisetin was the most potent — reducing senescent cell burden more effectively than quercetin, apigenin, luteolin, or other flavonoids tested in human adipose tissue and mouse models. The mechanism overlaps with quercetin (BCL-2/BCL-XL inhibition, PI3K suppression) but fisetin appears to have more potent BCL-2 family inhibition at equivalent concentrations. Importantly, fisetin also crosses the blood-brain barrier — making it relevant for neuronal senescence, which is increasingly recognized as a driver of cognitive decline.
The human data is limited but promising. A small pilot trial at Mayo Clinic tested fisetin 20 mg/kg/day × 2 consecutive days in older adults. Adipose tissue biopsies showed meaningful reductions in multiple senescent cell markers (p16, p21, SASP factors). A larger Phase II trial is underway. The intermittent dosing approach mirrors D+Q — senescent cells accumulate over months, not days, so periodic high-dose pulses are appropriate.
Fisetin also has independent neuroprotective and anti-inflammatory properties beyond its senolytic activity: it activates ERK (the signaling pathway for long-term memory formation), inhibits NF-κB-driven inflammation, and extends lifespan in multiple organisms. These properties make fisetin useful even before its senolytic applications — and together they create a genuinely broad longevity profile from an inexpensive supplement.
How it works
Senolytic — BCL-2 and PI3K Inhibition
Like D+Q, fisetin targets the senescent cell anti-apoptotic pathway (SCAP). Fisetin's primary senolytic mechanisms: BCL-2 and BCL-XL inhibition (reducing the anti-apoptotic proteins that keep senescent cells alive), PI3K/AKT pathway suppression (reducing the survival signaling senescent cells depend on), and reduction of p21-driven senescence maintenance. Fisetin appears to be more potent than quercetin specifically at BCL-2 inhibition, which may explain its superior senolytic activity in the Kirkland lab screening.
Neuroprotection — ERK Signaling and Memory
Fisetin activates ERK (extracellular signal-regulated kinase) in the hippocampus — the same signaling pathway activated during long-term memory formation. Fisetin administered to aged mice improved memory performance and increased hippocampal spine density. This ERK activation mechanism is independent of fisetin's senolytic activity and represents a direct neuroprotective and cognitive enhancement mechanism. Fisetin is one of very few compounds with evidence for both senolytic clearance AND direct cognitive enhancement.
NF-κB Anti-Inflammatory Effects
Fisetin inhibits NF-κB signaling, reducing production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). This anti-inflammatory effect is relevant both systemically (reducing SASP output from senescent cells that survive senolytic treatment) and neurologically (reducing neuroinflammation that impairs cognitive function in aging). The combination of senolytic, neuroprotective, and anti-inflammatory activities in a single compound makes fisetin unusual.
SIRT1 Activation
Fisetin activates SIRT1 — the same sirtuin that NAD+ precursors support — producing downstream deacetylation effects on NF-κB and p53. This SIRT1 activation contributes to fisetin's anti-inflammatory and pro-longevity effects through a mechanism that complements the NAD+/NMN approach.
What the research shows
What the community reports
Fisetin's community is the broadest of any senolytic — because the accessibility (supplement, no prescription, inexpensive) brings in a much wider audience than FOXO4-DRI or D+Q. The community includes both serious longevity researchers and casual biohackers adding it to their stack.
Common misconceptions
"Eating strawberries gives you the senolytic benefit."
Strawberries contain ~160 mcg/g of fisetin. To reach the 20 mg/kg study dose in a 70 kg person (1,400 mg), you'd need to eat approximately 8,750 grams (nearly 20 lbs) of strawberries per day. Dietary intake is irrelevant to the senolytic application — concentrated supplemental fisetin is required.
"Daily low-dose fisetin is the best protocol."
Senescent cells accumulate over months — they don't re-accumulate in days. Daily low-dose fisetin doesn't match the biology of the mechanism being targeted. The senolytic protocol is intermittent high-dose (2-3 consecutive days monthly or quarterly) — the same logic as D+Q and FOXO4-DRI. Daily low-dose may provide general anti-inflammatory and neuroprotective benefits but is not the senolytic approach.
"Fisetin alone is sufficient as a senolytic strategy."
Fisetin has excellent senolytic activity for a supplement-grade compound. But D+Q covers different cell types more comprehensively, and FOXO4-DRI has a different mechanism entirely. A layered senolytic approach (fisetin quarterly + D+Q once or twice yearly + FOXO4-DRI intermittently) addresses senescent cell clearance from multiple mechanistic angles — theorized to be more complete than any single agent.
Open PepperLedger to track your Fisetin protocol →
Free to join. No credit card. Ask the Coach how to structure a senolytic pulse protocol.
Free to join · No credit card · 23-day Pro trial included